|
| Press Releases |
|
 |
|
| Friday, June 13, 2025 |
|
|
Jacobson Pharma Announces FY2025 Annual Results |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing, and sale of essential medicines and specialty drugs, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2025 ("FY2025" or the "Reporting Period"). more info >> |
|
|
雅各臣公佈二零二五財年全年業績 持續經營業務溢利飈升43.1％至3.0億港元 |
| 從事基礎藥物及專科藥物研發、生產、市場推廣及銷售的領先企業 ─ 雅各臣科研製藥有限公司（「雅各臣」或「公司」；股份代號：2633.HK）今天公佈公司及其附屬公司（統稱「集團」）截至二零二五年三月三十一日止年度（「二零二五財年」或「報告期」）的全年業績。 more info >> |
|
|
雅各臣公布二零二五财年全年业绩 持续经营业务溢利飙升43.1％至3.0亿港元 |
| 从事基础药物及专科药物研发、生产、市场推广及销售的领先企业 ─ 雅各臣科研制药有限公司（「雅各臣」或「公司」；股份代号：2633.HK）今天公布公司及其附属公司（统称「集团」）截至二零二五年三月三十一日止年度（「二零二五财年」或「报告期」）的全年业绩。 more info >> |
|
| Friday, November 22, 2024 |
|
|
Jacobson Pharma Announces FY2025 Interim Results |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines and specialty drugs, today announced the interim results of the Company and its subsidiaries (collectively, the "Group") for the six months ended 30 September 2024 (the "Reporting Period"). more info >> |
|
|
雅各臣公佈二零二五財年中期業績 持續經營業務溢利飈升44.2% |
| 從事基礎藥物及專科藥物研發、生產、市場推廣及銷售的領先企業 ─ 雅各臣科研製藥有限公司（「雅各臣」或「公司」；股份代號：2633.HK）今天公佈公司及其附屬公司（統稱「集團」）於截至二零二四年九月三十日止六個月（「報告期」）的中期業績。 more info >> |
|
| Friday, November 25, 2022 |
|
|
雅各臣公布二零二三财年中期业绩 |
| 从事基础药物、专科药物及品牌医疗保健品研发、生产、市场推广及销售的领先企业 ─ 雅各臣科研制药有限公司 （「 雅各臣 」 或 「 公司 」；股份代号 2633.HK ) 今天公布公司及其附属公司（统称「集团」）于截至二零二二年九月三十日止年度（「报告期」）的中期业绩。 more info >> |
|
|
雅各臣公佈二零二三財年中期業績 |
| 從事基礎藥物、專科藥物及品牌醫療保健品研發、生產、市場推廣及銷售的領先企業 ─ 雅各臣科研製藥有限公司 （「 雅各臣 」 或 「 公司 」；股份代號 2633.HK ) 今天公佈公司及其附屬公司（統稱「集團」）於截至二零二二年九月三十日止年度（「報告期」）的中期業績。 more info >> |
|
|
Jacobson Pharma Announces FY2023 Interim Results |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the interim results of the Company and its subsidiaries (collectively the "Group") for the six months ended 30 September 2022 (the "Reporting Period"). more info >> |
|
| Wednesday, June 29, 2022 |
|
|
雅各臣公布二零二二财年全年业绩 |
从事基础药物、专科药物及品牌医疗保健品研发、生产、市场推广及销售的领先企业 ─ 雅各臣科研制药有限公司 （「 雅各臣 」或「 公司 」； 股份代号： 2633.HK )今天公布公司及其附属公司（统称「集团」）于截至二零二二年三月三十一日止年度（「二零二二财年」或「报告期」）的全年业绩。
more info >> |
|
|
雅各臣公佈二零二二財年全年業績 |
| 從事基礎藥物、專科藥物及品牌醫療保健品研發、生產、市場推廣及銷售的領先企業 ─ 雅各臣科研製藥有限公司 （「 雅各臣 」或「 公司 」； 股份代號： 2633.HK )今天公佈公司及其附屬公司（統稱「集團」）於截至二零二二年三月三十一日止年度（「二零二二財年」或「報告期」）的全年業績。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Focus Graphite Advances ESIA Reporting at Lac Knife and Accelerates Mineral Resource Expansion at Lac Tetepisca and Announces the Grant of Options and RSUs
Aug 14, 2025 06:59 HKT/SGT
|
|
|
Kangji Medical Receives Privatisation Proposal from a Consortium Led by Kangji Medical's Chairman, Zhong Ming, TPG and QIA to Advance Long-Term Strategic Vision
Aug 13, 2025 23:21 HKT/SGT
|
|
|
GEON Performance Solutions Achieves Great Place to Work Recognition Globally Second Year in a Row
Aug 13, 2025 23:18 HKT/SGT
|
|
|
AI Inference vs. AI Training: What Are the Differences?
Aug 13, 2025 23:03 HKT/SGT
|
|
|
Shoucheng Joins World Humanoid Robot Games - 88 Spectators Invited
Aug 13, 2025 22:33 HKT/SGT
|
|
|
MMG Announces 2025 Interim Results, Profit, Earnings and Cash up on Strong Copper Growth
Aug 13, 2025 22:31 HKT/SGT
|
|
|
Formerra Becomes North American Distributor for Syensqo PVDF
Aug 13, 2025 21:32 HKT/SGT
|
|
|
China Lilang Announces 2025 Interim Results
Aug 13, 2025 21:30 HKT/SGT
|
|
|
NMPA已受理亿胜生物关于EB12-20145P（HLX04-O）用于治疗湿性年龄相关性黄斑变性的生物制品许可申请
Aug 13, 2025 21:25 HKT/SGT
|
|
|
NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration
Aug 13, 2025 21:24: JST
|
|
|
NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration
Aug 13, 2025 20:24 HKT/SGT
|
|
|
NMPA已受理億勝生物關於EB12-20145P（HLX04-O）用於治療濕性年齡相關性黃斑變性的生物製品許可申請
Aug 13, 2025 20:24 HKT/SGT
|
|
|
潼關黃金獲納入MSCI全球小型股指數 資本市場影響力進一步提升
Aug 13, 2025 19:19 HKT/SGT
|
|
|
AsiaMedic Reports 26% Revenue Growth to S$16.6 million in 1H2025, Led by Strong Diagnostic Imaging Performance
Aug 13, 2025 14:00 HKT/SGT
|
|
|
74th China (Linyi) International Hardware Expo to Open September 5-7, 2025 in Shandong
Aug 13, 2025 13:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
